Company Performance Metrics
- Colin Dalton: CSO and co-founderPast Role: Neuraura, Co-founder and CTO
- Pierre Wijdenes: CPO and co-founderPast Role: Neuraura, Co-founder and CEO
Neuraura is leveraging their proprietary micro-electrodes to transform women’s reproductive and metabolic health with a wearable bioelectronic device for the treatment of PCOS. Neuraura is bringing to market the first effective, widely accessible treatment for PCOS as an over-the-counter, affordable device that augments the body's natural
processes rather than just masking the symptoms.
Neuraura is entering the market through an initial application in (pelvic) pain leveraging a predicate regulatory code (NUH) under an FDA 510(k) pathway. Once in market, Neuraura will escalate the device claims to the treatment of insulin resistance and other aspects of PCOS, leveraging targeted small-scale clinical studies as well as user data. Longer term, we are exploring a premium, reimbursed device for the treatment of pre-diabetes and diabetes.
